Long‐term follow‐up results of pediatric and adolescent patients with localized Ewing sarcoma treated based on stratified modalities
Open Access
- 21 February 2023
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (8) , 9409-9419
Abstract
Background: Compared with other pediatric tumors, little advances were achieved in studies on the stratified treatment in localized Ewing sarcoma. Most pediatric oncology groups treated Ewing sarcoma according to whether there was an existing metastasis, without involving more prognostic factors. In this study, patients with localized Ewing sarcoma were divided into resectable and unresectable groups at diagnosis and received chemotherapy with different intensity, for the purpose of achieving good efficacy, avoiding overtreatment and reducing unnecessary toxicity.Methods: A total of 143 patients with a median age of 10 years old diagnosed with localized Ewing sarcoma in this retrospective study were divided into two cohorts (Cohort 1, n = 42; Cohort 2, n = 101) and patients in Cohort 2 received chemotherapy with different intensity (Regimen 1, n = 52; Regimen 2, n = 49). Outcomes were analyzed using the Kaplan-Meier method to estimate event-free survival (EFS) and overall survival (OS), and the curves were compared using the log-rank test.Results: The 5-year EFS and 5-year OS for all the patients were 69.0% and 77.5%. The 5-year EFS for Cohort 1 and Cohort 2 were 76.0% and 66.1% (p = 0.31), and the 5-year OS were 83.0% and 75.1% (p = 0.30), respectively. In Cohort 2, the 5-year EFS rate of patients treated with Regimen 2 was significantly higher than that of patients treated with Regimen 1 (74.5% vs. 58.3%, p = 0.03).Conclusions: According to whether a grossly complete resection was received at the time of diagnosis, localized Ewing sarcoma patients in this study were stratified into two groups and received different intensities of chemotherapy, which achieved good efficacy and avoided overtreatment and reduced unnecessary toxicity.Keywords
This publication has 35 references indexed in Scilit:
- Malignant melanoma as second malignant neoplasm in long‐term childhood cancer survivors: A systematic reviewPediatric Blood & Cancer, 2012
- Ewing's sarcomaThe Lancet Oncology, 2010
- Ewing sarcoma demonstrates racial disparities in incidence‐related and sex‐related differences in outcomeCancer, 2009
- Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk PatientsJournal of Clinical Oncology, 2008
- Analysis of prognostic factors in ewing sarcoma family of tumorsCancer, 2007
- Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: An analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998Acta Oncologica, 2006
- Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Chest WallAnnals of Surgery, 2003
- Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651Journal of Clinical Oncology, 2003
- Ewing sarcoma of the ribResults of an intergroup study with analysis of outcome by timing of resectionThe Journal of Thoracic and Cardiovascular Surgery, 2000